PURPOSE: In preparation for a phase I clinical trial using a combined cytotoxic/immunotherapeutic strategy with adenoviruses (Ad) expressing Flt3L (Ad-Flt3L) and thymidine kinase (Ad-TK) to treat glioblastoma (GBM), we tested the hypothesis that Ad-TK+GCV would be the optimal tumor-killing agent in relation to efficacy and safety when compared with other proapoptotic approaches. EXPERIMENTAL DESIGN: The efficacy and neurotoxicity of Ad-TK+GCV was compared with Ads encoding the proapoptotic cytokines [tumor necrosis factor-alpha, tumor necrosis factor-related apoptosis-inducing factor (TRAIL), and Fas ligand (FasL)], alone or in combination with Ad-Flt3L. In rats bearing small GBMs (day 4), only Ad-TK+GCV or Ad-FasL improved survival. RESULTS: In rats bearing large GBMs (day 9), the combination of Ad-Flt3L with Ad-FasL did not improve survival over FasL alone, whereas Ad-Flt3L combined with Ad-TK+GCV led to 70% long-term survival. Expression of FasL and TRAIL caused severe neuropathology, which was not encountered when we used Ad-TK+/-Ad-Flt3L. In vitro, all treatments elicited release of high mobility group box 1 protein (HMGB1) from dying tumor cells. In vivo, the highest levels of circulating HMGB1 were observed after treatment with Ad-TK+GCV+Ad-Flt3L; HMGB1 was necessary for the therapeutic efficacy of AdTK+GCV+Ad-Flt3L because its blockade with glycyrrhizin completely blocked tumor regression. We also showed the killing efficacy of Ad-TK+GCV in human GBM cell lines and GBM primary cultures, which also elicited release of HMGB1. CONCLUSIONS: Our results indicate that Ad-TK+GCV+Ad-Flt3L exhibit the highest efficacy and safety profile among the several proapoptotic approaches tested. The results reported further support the implementation of this combined approach in a phase I clinical trial for GBM.
PURPOSE: In preparation for a phase I clinical trial using a combined cytotoxic/immunotherapeutic strategy with adenoviruses (Ad) expressing Flt3L (Ad-Flt3L) and thymidine kinase (Ad-TK) to treat glioblastoma (GBM), we tested the hypothesis that Ad-TK+GCV would be the optimal tumor-killing agent in relation to efficacy and safety when compared with other proapoptotic approaches. EXPERIMENTAL DESIGN: The efficacy and neurotoxicity of Ad-TK+GCV was compared with Ads encoding the proapoptotic cytokines [tumor necrosis factor-alpha, tumor necrosis factor-related apoptosis-inducing factor (TRAIL), and Fas ligand (FasL)], alone or in combination with Ad-Flt3L. In rats bearing small GBMs (day 4), only Ad-TK+GCV or Ad-FasL improved survival. RESULTS: In rats bearing large GBMs (day 9), the combination of Ad-Flt3L with Ad-FasL did not improve survival over FasL alone, whereas Ad-Flt3L combined with Ad-TK+GCV led to 70% long-term survival. Expression of FasL and TRAIL caused severe neuropathology, which was not encountered when we used Ad-TK+/-Ad-Flt3L. In vitro, all treatments elicited release of high mobility group box 1 protein (HMGB1) from dying tumor cells. In vivo, the highest levels of circulating HMGB1 were observed after treatment with Ad-TK+GCV+Ad-Flt3L; HMGB1 was necessary for the therapeutic efficacy of AdTK+GCV+Ad-Flt3L because its blockade with glycyrrhizin completely blocked tumor regression. We also showed the killing efficacy of Ad-TK+GCV in human GBM cell lines and GBM primary cultures, which also elicited release of HMGB1. CONCLUSIONS: Our results indicate that Ad-TK+GCV+Ad-Flt3L exhibit the highest efficacy and safety profile among the several proapoptotic approaches tested. The results reported further support the implementation of this combined approach in a phase I clinical trial for GBM.
Authors: C Cowsill; T D Southgate; G Morrissey; R A Dewey; A E Morelli; T C Maleniak; Z Forrest; D Klatzmann; G W Wilkinson; P R Löwenstein; M G Castro Journal: Gene Ther Date: 2000-04 Impact factor: 5.250
Authors: Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: James F Curtin; Marianela Candolfi; Weidong Xiong; Pedro R Lowenstein; Maria G Castro Journal: Mol Cancer Ther Date: 2008-03 Impact factor: 6.261
Authors: M Enderlin; E V Kleinmann; S Struyf; C Buracchi; A Vecchi; R Kinscherf; F Kiessling; S Paschek; S Sozzani; J Rommelaere; J J Cornelis; J Van Damme; C Dinsart Journal: Cancer Gene Ther Date: 2008-08-01 Impact factor: 5.987
Authors: Robert J Schmittling; Gary E Archer; Duane A Mitchell; Amy Heimberger; Charles Pegram; James E Herndon; Henry S Friedman; Darell D Bigner; John H Sampson Journal: J Immunol Methods Date: 2008-09-04 Impact factor: 2.303
Authors: Roberta Palumbo; Maurilio Sampaolesi; Francesco De Marchis; Rossana Tonlorenzi; Sara Colombetti; Anna Mondino; Giulio Cossu; Marco E Bianchi Journal: J Cell Biol Date: 2004-01-26 Impact factor: 10.539
Authors: Yohei Mineharu; Gwendalyn D King; A K M G Muhammad; Serguei Bannykh; Kurt M Kroeger; Chunyan Liu; Pedro R Lowenstein; Maria G Castro Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Daniel Larocque; Nicholas S R Sanderson; Josée Bergeron; James F Curtin; Joe Girton; Mia Wibowo; Niyati Bondale; Kurt M Kroeger; Jieping Yang; Liliana M Lacayo; Kevin C Reyes; Catherine Farrokhi; Robert N Pechnick; Maria G Castro; Pedro R Lowenstein Journal: Proc Natl Acad Sci U S A Date: 2010-07-26 Impact factor: 11.205
Authors: Marianela Candolfi; Weidong Xiong; Kader Yagiz; Chunyan Liu; A K M G Muhammad; Mariana Puntel; David Foulad; Ali Zadmehr; Gabrielle E Ahlzadeh; Kurt M Kroeger; Matthew Tesarfreund; Sharon Lee; Waldemar Debinski; Dhruv Sareen; Clive N Svendsen; Ron Rodriguez; Pedro R Lowenstein; Maria G Castro Journal: Proc Natl Acad Sci U S A Date: 2010-10-28 Impact factor: 11.205
Authors: Nathan VanderVeen; Nicholas Raja; Elizabeth Yi; Henry Appelman; Philip Ng; Donna Palmer; Daniel Zamler; Marta Dzaman; Pedro R Lowenstein; Maria G Castro Journal: Hum Gene Ther Methods Date: 2016-04-28 Impact factor: 2.396
Authors: Gwendalyn D King; A K M Ghulam Muhammad; Daniel Larocque; Kyle R Kelson; Weidong Xiong; Chunyan Liu; Nicholas S R Sanderson; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein Journal: Mol Ther Date: 2011-04-19 Impact factor: 11.454
Authors: Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein Journal: Expert Opin Biol Ther Date: 2014-04-29 Impact factor: 4.388
Authors: Hikmat Assi; Marianela Candolfi; Gregory Baker; Yohei Mineharu; Pedro R Lowenstein; Maria G Castro Journal: Neurosci Lett Date: 2012-08-10 Impact factor: 3.046
Authors: Weidong Xiong; Marianela Candolfi; Chunyan Liu; A K M Ghulam Muhammad; Kader Yagiz; Mariana Puntel; Peter F Moore; Julie Avalos; John D Young; Dorothy Khan; Randy Donelson; G Elizabeth Pluhar; John R Ohlfest; Kolja Wawrowsky; Pedro R Lowenstein; Maria G Castro Journal: PLoS One Date: 2010-06-11 Impact factor: 3.240